التفاصيل البيبلوغرافية
| العنوان: |
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. |
| المؤلفون: |
Özdemir, Berna C.1 (AUTHOR) Berna.oezdemir@insel.ch, Espinosa da Silva, Cristina2,3 (AUTHOR), Arangalage, Dimitri4 (AUTHOR), Monney, Pierre5 (AUTHOR), Guler, Sabina A.6 (AUTHOR), Huynh-Do, Uyen7 (AUTHOR), Stirnimann, Guido8 (AUTHOR), Possamai, Lucia9 (AUTHOR), Trepp, Roman10 (AUTHOR), Hoepner, Robert11 (AUTHOR), Salmen, Anke11 (AUTHOR), Gerard, Camille L.12,13 (AUTHOR), Hruz, Petr14 (AUTHOR), Christ, Lisa15 (AUTHOR), Rothschild, Sacha I.16,17 (AUTHOR) |
| المصدر: |
Cancer Immunology, Immunotherapy. Jul2023, Vol. 72 Issue 7, p1991-2001. 11p. |
| مصطلحات موضوعية: |
*DRUG side effects, *ADVERSE health care events, *EARLY diagnosis, *CANCER patients, *IMMUNE checkpoint inhibitors |
| مستخلص: |
Immune checkpoint inhibitors (ICIs) have fundamentally changed the treatment landscape of various cancers. While ICI treatments result in improved survival, quality of life and are cost-effective, the majority of patients experience at least one immune-related adverse event (irAE). Many of these side effects cause little discomfort or are asymptomatic; however, irAEs can affect any organ and are potentially life-threatening. Consequently, early diagnosis and appropriate treatment of irAEs are critical for optimizing long-term outcomes and quality of life in affected patients. Some irAEs are diagnosed according to typical symptoms, others by abnormal findings from diagnostic tests. While there are various guidelines addressing the management of irAEs, recommendations for the early recognition of irAEs as well as the optimal extent and frequency of laboratory tests are mostly lacking. In clinical practice, blood sampling is usually performed before each ICI administration (i.e., every 2–3 weeks), often for several months, representing a burden for patients as well as health care systems. In this report, we propose essential laboratory and functional tests to improve the early detection and management of irAEs and in cancer patients treated with ICIs. These multidisciplinary expert recommendations regarding essential laboratory and functional tests can be used to identify possible irAEs at an early time point, initiate appropriate interventions to improve patient outcomes, and reduce the burden of blood sampling during ICI treatment. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder